SGLT2 inhibitors

systematic review meta-analysis network meta-analysis

Select diabetes type 2 All type of patient       add-on standard treatmentbi-tri-therapy with INS bi-tri-therapy with MET+/-PIObitherapy with DDP-4bitherapy with METbitherapy with SUbitherapy with TZDCV safety trialmonotherapytritherapy with MET+SU canagliflozindapagliflozinempagliflozinsaxagliptin      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result
diabetes type 2
dapagliflozin
Yang, 2015      NCT	dapagliflozin					-
Nauck, 2011      NCT	dapagliflozin	dlipizide add on metformin				-
List (MB102008), 2009        NCT	dapagliflozin	placebo			Exploratory	-
Ferrannini (MB102013), 2010        NCT	dapagliflozin	placebo			Low risk of bias	-
Komoroski (MB102007), 2009      NCT	dapagliflozin	placebo			Exploratory	-
KOhan      NCT	dapagliflozin	placebo			Low risk of bias	-
Kohan      NCT	dapagliflozin	placebo				-
Kohan      NCT	dapagliflozin	placebo				-
Kaku, 2014      NCT	dapagliflozin	placebo				-
Wilding (MB102009), 2009        NCT	dapagliflozin	placebo (add on insulin)			Low risk of bias	-
Wilding, 2012              NCT	dapagliflozin	placebo (add on insulin)				-
Mathieu, 2015      NCT	dapagliflozin	placebo (add on MET + SAXA)				-
Bolinder, 2012          NCT	dapagliflozin	placebo (add on MET)				-
Bailey (MB102014), 2010          NCT	dapagliflozin	placebo (add on MET)			Low risk of bias	-
Schumm-Draeger , 2015      NCT	dapagliflozin	placebo (add on MET)				-
Matthaei, 2015      NCT	dapagliflozin	placebo (add on MET+SU)				-
Rosenstock, 2012        NCT	dapagliflozin	placebo (add on TZD)				-
MB102035    NCT	dapagliflozin	placebo (on top standard treatment)				-
Cefalu, 2015        NCT	dapagliflozin	placebo (on top standard treatment)				-
Leiter, 2016      NCT	dapagliflozin	placebo (on top standard treatment)				-
MB102073    NCT	dapagliflozin	placebo (on top standard treatment)				-
Weber      NCT	dapagliflozin	placebo (on top standard treatment)				-
MB102061    NCT	dapagliflozin	placebo add on DPP-4				-
Rosenstock, 2015      NCT	dapagliflozin	Saxagliptin (add on MET)				-
Kohan      NCT	dapagliflozin + merformin	dapagliflozin				-
Strojek, 2011          NCT	dapagliflozin + Glimepiride	glimepiride				-
MB102034, 2016      NCT	dapagliflozin + merformin	metformin or dapa				-
empagliflozin
Kadowaki, 2013	empagliflozin					-
Kadowaki , 2014	empagliflozin					-
Ridderstrale, 2014        NCT	empagliflozin	Glimepiride + MET				-
DeFronzo, 2015        NCT	empagliflozin	linagliptin (add-on MET)				-
Lewin, 2015      NCT	empagliflozin	linagliptin (monotherapy)				-
EMPA-REG OUTCOME    NCT	empagliflozin	placebo				-
Ferrannini, 2013      NCT	empagliflozin	placebo				-
EMPA-REG MONO (Roden) vs placebo, 2013      NCT	empagliflozin	placebo				-
Kadowaki, 2015      NCT	empagliflozin	placebo				-
Barnett, 2014      NCT	empagliflozin	placebo				-
EMPA-REG PIO (Kovacs), 2013      NCT	empagliflozin	placebo (add on MET+/-PIO)				-
Rosenstock DOUBLON ???, 2013	empagliflozin	placebo (add-on INS)				-
Rosenstock (1245.49), 2014      NCT	empagliflozin	placebo (add-on INS+/-MET)				-
Rosenstock, 2013      NCT	empagliflozin	placebo (add-on MET)				-
Ross, 2015	empagliflozin	placebo (add-on MET)				-
EMPA-REG MET (Haring), 2014      NCT	empagliflozin	placebo (add-on MET)				-
Araki, 2015      NCT	empagliflozin	placebo (add-on standard treatment)				-